PURPOSE: Her-2/neu and the insulin-like growth factor-1 receptor (IGF-1R) share common postreceptor-signaling pathways, and pre-clinical models have implicated IGF-1R-signaling in resistance to treatment with the anti-Her-2/neu antibody trastuzumab. The present analysis was performed to evaluate the clinical relevance of IGF-1R expression within the context of trastuzumab-based therapy. PATIENTS AND METHODS: We performed immunohistochemical (IHC) analysis for IGF-1R expression in tumor specimens from 72 patients receiving trastuzumab-based treatment for Her-2/neu-overexpressing metastatic breast cancer at a single institution. IGF-1R status was evaluated using different cut-offs for positivity regarding staining intensity and staining pattern. IGF-1R positivity was then correlated with clinical patient and biological tumor characteristics and the clinical course of disease of patients under trastuzumab-based therapy. RESULTS: No pattern or intensity of staining for IGF-1R correlated with any of the clinical or biological characteristics. Likewise, response, clinical benefit, progression-free and overall survival were independent of IGF-1R expression in both, univariate and multivariate analyses (all P>0.05). CONCLUSIONS: We conclude that IGF-1R expression is not a major predictor of the clinical efficacy of trastuzumab-based treatment in patients with Her-2/neu- overexpressing metastatic breast cancer.
PURPOSE:Her-2/neu and the insulin-like growth factor-1 receptor (IGF-1R) share common postreceptor-signaling pathways, and pre-clinical models have implicated IGF-1R-signaling in resistance to treatment with the anti-Her-2/neu antibody trastuzumab. The present analysis was performed to evaluate the clinical relevance of IGF-1R expression within the context of trastuzumab-based therapy. PATIENTS AND METHODS: We performed immunohistochemical (IHC) analysis for IGF-1R expression in tumor specimens from 72 patients receiving trastuzumab-based treatment for Her-2/neu-overexpressing metastatic breast cancer at a single institution. IGF-1R status was evaluated using different cut-offs for positivity regarding staining intensity and staining pattern. IGF-1R positivity was then correlated with clinical patient and biological tumor characteristics and the clinical course of disease of patients under trastuzumab-based therapy. RESULTS: No pattern or intensity of staining for IGF-1R correlated with any of the clinical or biological characteristics. Likewise, response, clinical benefit, progression-free and overall survival were independent of IGF-1R expression in both, univariate and multivariate analyses (all P>0.05). CONCLUSIONS: We conclude that IGF-1R expression is not a major predictor of the clinical efficacy of trastuzumab-based treatment in patients with Her-2/neu- overexpressing metastatic breast cancer.
Authors: H J Burstein; I Kuter; S M Campos; R S Gelman; L Tribou; L M Parker; J Manola; J Younger; U Matulonis; C A Bunnell; A H Partridge; P G Richardson; K Clarke; L N Shulman; E P Winer Journal: J Clin Oncol Date: 2001-05-15 Impact factor: 44.544
Authors: A D Seidman; M N Fornier; F J Esteva; L Tan; S Kaptain; A Bach; K S Panageas; C Arroyo; V Valero; V Currie; T Gilewski; M Theodoulou; M E Moynahan; M Moasser; N Sklarin; M Dickler; G D'Andrea; M Cristofanilli; E Rivera; G N Hortobagyi; L Norton; C A Hudis Journal: J Clin Oncol Date: 2001-05-15 Impact factor: 44.544
Authors: M E Balañá; L Labriola; M Salatino; F Movsichoff; G Peters; E H Charreau; P V Elizalde Journal: Oncogene Date: 2001-01-04 Impact factor: 9.867
Authors: Charles L Vogel; Melody A Cobleigh; Debu Tripathy; John C Gutheil; Lyndsay N Harris; Louis Fehrenbacher; Dennis J Slamon; Maureen Murphy; William F Novotny; Michael Burchmore; Steven Shak; Stanford J Stewart; Michael Press Journal: J Clin Oncol Date: 2002-02-01 Impact factor: 44.544
Authors: Yoichi Nagata; Keng-Hsueh Lan; Xiaoyan Zhou; Ming Tan; Francisco J Esteva; Aysegul A Sahin; Kristine S Klos; Ping Li; Brett P Monia; Nina T Nguyen; Gabriel N Hortobagyi; Mien-Chie Hung; Dihua Yu Journal: Cancer Cell Date: 2004-08 Impact factor: 31.743
Authors: M D Pegram; A Lipton; D F Hayes; B L Weber; J M Baselga; D Tripathy; D Baly; S A Baughman; T Twaddell; J A Glaspy; D J Slamon Journal: J Clin Oncol Date: 1998-08 Impact factor: 44.544
Authors: Eduardo Sanabria-Figueroa; Siobhan M Donnelly; Kevin C Foy; Meghan C Buss; Robert C Castellino; Elisavet Paplomata; Latonia Taliaferro-Smith; Pravin T P Kaumaya; Rita Nahta Journal: Mol Pharmacol Date: 2014-11-12 Impact factor: 4.436
Authors: Gal Lenz; Angelica Hamilton; Shuhui Geng; Teresa Hong; Markus Kalkum; Jamil Momand; Susan E Kane; Janice M Huss Journal: Clin Cancer Res Date: 2017-11-27 Impact factor: 12.531
Authors: Monica M Reinholz; Beiyun Chen; Amylou C Dueck; Kathleen Tenner; Karla Ballman; Darren Riehle; Robert B Jenkins; Xochiquetzal J Geiger; Ann E McCullough; Edith A Perez Journal: Clin Cancer Res Date: 2017-05-22 Impact factor: 12.531